<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02953145</url>
  </required_header>
  <id_info>
    <org_study_id>45664</org_study_id>
    <nct_id>NCT02953145</nct_id>
  </id_info>
  <brief_title>The Use of Fibrin Sealant to Reduce Post Operative Pain in Cleft Palate Surgery</brief_title>
  <official_title>The Use of Fibrin Sealant to Reduce Post Operative Pain in Cleft Palate Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cleft Palate is a condition which affects up to 1 in 500 live births. Current treatment is
      surgery to correct the underlying anomaly. Children born with cleft palate typically undergo
      surgery at age 12 months. Standard ways to stop surgical bleeding include direct pressure and
      the use of electrocautery (burning of the tissue). Other products are available to help
      lessen blood loss. One of these includes a fibrin sealant. Fibrin is the key component of a
      blood clot. When a fibrin sealant is applied there are a variety of potential benefits other
      than bleeding control. One of these is decreased pain post operatively It is the
      investigators belief that the use of a fibrin sealant, Tisseel, in cleft palate surgery will
      decrease pain and enhance the recovery of children who undergo cleft palate repair.

      The proposed study will randomly select children undergoing cleft palate repair to have
      tisseel used on the incision. Through statistical tests 40 children will be recruited (20 to
      have tisseel used and 20 with no tisseel). The use of tisseel will be known to the surgeon
      but not to the recovery room or ward nursing staff. Post operatively, the FLACC pain scale
      will be used to score the pain of the children throughout their admission to the Stollery
      children's hospital. The amount of pain controlling medication required as well as time to
      discharge will also be recorded. Statistical analysis of the data will be performed using
      accepted methods. Overall, the investigators hope to show that fibrin sealant, tisseel, will
      less the amount of post operative pain experienced by children undergoing cleft palate
      repair.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cleft palate is a condition which affects up to 1:500 births. Current practice is that
      children are enrolled in a multidisciplinary care team and undergo primary cleft palate
      repair at 12 months of age. These children are admitted to hospital overnight for observation
      of airway compromise, bleeding and analgesics. The use of fibrin sealant is gaining
      popularity and its use in pediatric surgery is becoming more commonplace. It acts as both a
      hemostatic agent as well as an adhesive. A review of the current literature on fibrin sealant
      has shown that in adults and children it may decrease post operative inflammation and pain.
      In 1994 Moralee et al published that the use of fibrin sealant in tonsillectomy patients in
      lieu of diathermy resulted in decreased pain in the early post operative period and that it
      was equally effective as a hemostatic method. Another study published in 2005 by healy et al
      showed that when fibrin sealant was applied to the donor site from a thigh split thickness
      skin graft patients experienced significantly less pain over a 14 day study period. Tisseel
      is a safe product when used appropriately. It is contraindicated for injection
      intra-arterially and in those with allergy. It is derived from plasma however viral
      transmission has not been shown to occur in this product. A full product monograph is
      available. It is the investigators hypothesis that the use of tisseel in pediatric patients
      undergoing cleft palate repair will result in decreased post operative pain.

      The proposed study is a prospective randomized control trial. The control group will have
      electrocautery as the primary method of hemostasis control and the treatment group will have
      tisseel applied to the incision. The primary outcome of the study is post operative pain.
      Secondary outcomes will be the amount of analgesics required during the hospital admission,
      time to discharge, time to first feeding, minor complication rates- infection, dehiscence,
      respiratory compromise, and long term sequelae- oronasal fistula formation, need for
      revision, velopharynegal insufficiency. Statistical calculations for sample size have
      determined that 16 patients will be needed in each group. This was calculated based on an
      alpha of 0.05 and power(beta) of 0.8. Statistical significance will be set as p&lt;0.05.

      Recruitment will be directed at parents/guardians of patients to undergo cleft palate repair.
      Details of the study will be explained to parents pre-operatively. Currently the pediatric
      plastic surgeons at the Stollery Children's Hospital use tisseel in their repair techniques
      however the investigators do not have concrete data suggesting it has a clear benefit for
      this procedure. Two surgeons will be enrolling patients and performing surgeries
      independently with or without the assistance of residents and/or medical students. After
      informed consent by the primary decision maker, the patient will be randomized, via consealed
      envelop, to have tisseel used or have electrocautery used as a hemostatic mechanism. The
      parents/guardians will be blinded to the randomization. The operating room staff will know
      the results of the randomization and will need to prepare the Tisseel product. All other
      health care providers caring for the patient in the recovery period will be blinded to the
      randomization. Post-operative pain scores will be determined using the FLACC (Face, Legs,
      Activity, Cry, Consolability) scoring system. This system is a validated objective pain
      scoring system used in young children post procedure. Patients will be assessed in the
      standard fashion. Pain scores and analgesic medications given will be recorded as per current
      nursing policy as well as on the study record which will be placed in the patient's chart.
      Parents will be shown how to assess FLACC scores and if patient is discharged prior to 72
      hours, the parent or guardian will be asked to record the FLACC score at certain time points.
      The record of time to first feeding will be recorded on the study record form. Patients will
      be discharged from hospital when current criteria for safe discharge are met. Clinic follow
      up will be conducted in the current standard method at the surgeon's discretion. It will be
      noted on the patient's hospital chart that they were enrolled in this study in order to track
      long-term outcomes listed above.

      Student t-test will be used to compare the outcome data. Demographic parameters will be
      collected to validate the randomization of the study groups. Age at time of surgery,
      associated congenital malformations including cleft lip and prior orthodontic
      surgery/interventions will be recorded and stored in a password protected data storage
      device. Results of the study will be made available to the parent/guardians of the study
      patients. It is estimated that the study will require one year of recruitment and data
      collection for the primary outcome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 30, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post operative pain</measure>
    <time_frame>time 1 hour post operation</time_frame>
    <description>FLACC scores will be determined by blinded ward nurses and/or caregiver of the patient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post operative pain</measure>
    <time_frame>time 2 hours post operation</time_frame>
    <description>FLACC scores will be determined by blinded ward nurses and/or caregiver of the patient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post operative pain</measure>
    <time_frame>time 4 hours post operation</time_frame>
    <description>FLACC scores will be determined by blinded ward nurses and/or caregiver of the patient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post operative pain</measure>
    <time_frame>time 6 hours post operation</time_frame>
    <description>FLACC scores will be determined by blinded ward nurses and/or caregiver of the patient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post operative pain</measure>
    <time_frame>time 12 hours post operation</time_frame>
    <description>FLACC scores will be determined by blinded ward nurses and/or caregiver of the patient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post operative pain</measure>
    <time_frame>time 24 hours post operation</time_frame>
    <description>FLACC scores will be determined by blinded ward nurses and/or caregiver of the patient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post operative pain</measure>
    <time_frame>time 48 hours post operation</time_frame>
    <description>FLACC scores will be determined by blinded ward nurses and/or caregiver of the patient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post operative pain</measure>
    <time_frame>time 72 hours post operation</time_frame>
    <description>FLACC scores will be determined by blinded ward nurses and/or caregiver of the patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Requirement for analgesia</measure>
    <time_frame>From immediate post operative period up to 5 days</time_frame>
    <description>Any analgesic given to the patient will be recorded and compared for the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge</measure>
    <time_frame>From immediate post operative period up to 5 days</time_frame>
    <description>Patients are discharged from hospital when they are feeding adequately, pain is controlled and there are no other complications. The time when the patient meets discharge criteria as well as the time they actually leave the ward will be recorded and assessed in this study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first feeding</measure>
    <time_frame>From immediate post operative period up to 5 days</time_frame>
    <description>The time to successful feeding can be used as a marker for tolerable pain post operatively. The time when the patient first feeds successfully will be recorded and compared for the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oronasal fistula</measure>
    <time_frame>Immediately post operatively until 2 years post operatively.</time_frame>
    <description>Patients will be followed in the cleft lip and palate clinic . For the two years post operatively, repaired cleft palates will be examined for the presence of oronasal fistula.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cleft Palate</condition>
  <arm_group>
    <arm_group_label>Tisseel applied</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, the fibrin sealant Tisseel will be applied as a hemostasis agent in patients undergoing primary palatoplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No fibrin sealant</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In this group, no fibrin sealant will be applied intra-operatively. Standard measures, such as electrocautery, will be used for hemostasis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tisseel</intervention_name>
    <description>Tisseel will be applied to open areas lateral to the cleft palate repair</description>
    <arm_group_label>Tisseel applied</arm_group_label>
    <other_name>fibrin sealant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergoing primary cleft palate repair (palatoplasty)

          -  Informed consent from parent(s) or guardian(s)

        Exclusion Criteria:

          -  Allergy to any component of Tisseel

          -  failure to obtain informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaret L Olson, MD FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Curtis R Budden, MD B.Sc</last_name>
    <phone>780-232-2237</phone>
    <email>budden@ualberta.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jaret L Olson, MD FRCSC</last_name>
    <phone>780-407-8108</phone>
    <email>jolson@ualberta.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stollery Alberta Children's hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7804071591</phone>
    </contact>
    <investigator>
      <last_name>Jaret L Olson, MD FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Curtis R Budden, MD B.Sc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Davis BR, SÃ¡ndor GK. Use of fibrin glue in maxillofacial surgery. J Otolaryngol. 1998 Apr;27(2):107-12.</citation>
    <PMID>9572465</PMID>
  </reference>
  <reference>
    <citation>Healy C, Greig AV, Murphy AD, Powell C, Pinder RJ, Saour S, Abela C, Knight W, Geh JL. Prospective randomized controlled trial: fibrin sealant reduces split skin graft donor-site pain. Plast Reconstr Surg. 2013 Jul;132(1):139e-46e. doi: 10.1097/PRS.0b013e318299c6f4.</citation>
    <PMID>23806933</PMID>
  </reference>
  <reference>
    <citation>MacGillivray TE. Fibrin sealants and glues. J Card Surg. 2003 Nov-Dec;18(6):480-5. Review.</citation>
    <PMID>14992096</PMID>
  </reference>
  <reference>
    <citation>Merkel SI, Voepel-Lewis T, Shayevitz JR, Malviya S. The FLACC: a behavioral scale for scoring postoperative pain in young children. Pediatr Nurs. 1997 May-Jun;23(3):293-7.</citation>
    <PMID>9220806</PMID>
  </reference>
  <reference>
    <citation>Moralee SJ, Carney AS, Cash MP, Murray JA. The effect of fibrin sealant haemostasis on post-operative pain in tonsillectomy. Clin Otolaryngol Allied Sci. 1994 Dec;19(6):526-8.</citation>
    <PMID>7895385</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2015</study_first_submitted>
  <study_first_submitted_qc>October 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Cleft Palate</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

